Vectura Group plc has received marketing authorization in Romania for AirFluSal Forspiro, an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease. The receipt of the Romanian marketing authorization by Sandoz triggers a milestone payment to Vectura of €1.5 million. Romania has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD.

The product's safety, efficacy and equivalence have been proven in multiple clinical trials. The company initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal Forspiro by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence.